Portal de Periódicos da CAPES

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

2023; Lippincott Williams & Wilkins; Volume: 41; Issue: 10 Linguagem: Inglês

10.1200/jco.22.02572

1527-7755

Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, Fabrice André, Attila Tordai, Jaime Mejia, W. Fraser Symmans, Ana M. González-Angulo, Bryan T. Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobágyi, Lajos Pusztai,

HER2/EGFR in Cancer Research

Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC.